Allogene Therapeutics, Inc.

ALLOSEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1737287

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$22.0K	$95.0K	$114.1M	$0.00	$0.00
Research and Development Expense	$192.3M	$242.9M	$220.2M	$193.0M	$144.5M
Operating Expenses	$273.2M	$327.8M	$294.3M	$258.2M	$202.0M
Operating Income (Loss)	-$273.2M	-$327.7M	-$180.2M	-$258.2M	-$202.0M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$16.1M	$472.0K	-$1.9M	$8.0M	$17.1M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$257.1M	-$327.3M	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$548.7M	$642.8M	$978.1M	$1.0B	$1.2B
Assets, Current	$303.4M	$459.1M	$469.7M	$471.3M	$845.1M
Cash and Cash Equivalents, at Carrying Value	$75.2M	$83.2M	$84.5M	$173.3M	$183.4M
Liabilities	$126.5M	$130.6M	$112.8M	$122.2M	$148.2M
Liabilities, Current	$35.5M	$37.1M	$36.6M	$48.2M	$94.3M
Accounts Payable, Current	$5.4M	$5.9M	$8.7M	$10.3M	$10.4M
Stockholders' Equity Attributable to Parent	$512.2M	$666.9M	$1.0B	$629.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$200.3M	-$237.7M	-$184.8M	-$115.1M	-$137.3M
Net Cash Provided by (Used in) Investing Activities	$75.7M	$163.3M	$163.7M	-$505.1M	$164.1M
Net Cash Provided by (Used in) Financing Activities	$116.7M	$95.7M	$12.0M	$633.6M	$59.0M
Payments to Acquire Property, Plant, and Equipment	$694.0K	$1.5M	$21.4M	$66.0M	$50.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)